What are Medline, Inc. 's total assets?

Medline, Inc. (MDLN) holds $39.0B in total assets.

How much debt does Medline, Inc. have?

Medline, Inc. carries $12.6B in total debt against $11.3B of shareholders' equity, a debt-to-equity ratio of 1.11.

How much cash does Medline, Inc. have?

Medline, Inc. holds $2.2B in cash and equivalents.

Can Medline, Inc. cover its short-term obligations?

Its current ratio is 4.41 — current assets exceed current liabilities.

Where does Medline, Inc. 's balance sheet data come from?

Every line is extracted from Medline, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Medline, Inc. MDLN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23
Cash and cash equivalents	$1.94B+677%	$250M—	——
Restricted cash	$3M—	——	——
Accounts receivable, net	——	$3.41B+2,129%	$153M—
Inventories	——	$4.86B+1,196%	-$444M—
Raw materials	$748M—	——	——
Finished goods	$4.02B—	——	——
Prepaid expenses and other current assets	$438M+10.1%	$398M—	——
Total current assets	$10.68B+29.1%	$8.27B—	——
Property and equipment, net	$4.78B+4.0%	$4.6B—	——
Accumulated depreciation	$2.82B—	——	——
Goodwill	$8.08B+0.2%	$8.07B+7.1%	$7.53B—
Intangible assets, net	$10.06B-30.9%	$14.56B—	——
Deferred tax assets	——	-$18M+21.7%	-$23M—
Other non-current assets	$472M-3.1%	$487M—	——
Total assets	$38.48B+7.0%	$35.98B—	——
Accounts payable	——	$948.5M+597%	$136M—
Accrued expenses	$1.45B-2.7%	$1.49B—	——
Accrued compensation	$323M—	——	——
Current portion of long-term debt	$1M-50.0%	$2M—	——
Operating lease liabilities, current	$66M-13.2%	$76M—	——
Short-term borrowings	$1M-50.0%	$2M—	——
Income taxes payable	$24M—	——	——
Accrued interest	$144M—	——	——
Total current liabilities	$2.49B+2.0%	$2.44B—	——
Long-term debt	$12.48B-24.0%	$16.42B—	——
Operating Lease Liabilities (Total)	$452M+11.6%	$405M—	——
Other non-current liabilities	$682M+14.0%	$598M—	——
Total noncurrent liabilities	$16.71B-1.8%	$17.01B—	——
Total liabilities	$29M-99.9%	$19.45B—	——
Preferred stock	$0—	——	——
Additional paid-in capital	$10.72B—	——	——
Retained earnings	-$7M—	——	——
Accumulated other comprehensive income (loss)	$27M+145%	$11M—	——
Noncontrolling interests	$8.55B—	——	——
Total stockholders' equity	$10.74B—	——	——
Total liabilities and stockholders' equity	$38.48B+7.0%	$35.98B—	——
Allowance for Doubtful Accounts	$152M—	——	——
Allowance for Doubtful Accounts Receivable (Current)	$152M—	——	——
Finished goods	$4.02B—	——	——
Work in process and raw materials	$748M—	——	——
Other current assets	$438M+10.1%	$398M—	——
Inventory LIFO Reserve	$359M—	——	——
Other Inventory, Net	$44M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$23.03B-0.4%	$23.11B—	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——
Finite Lived Intangible Assets - Gross	$12.88B—	——	——
Intangible Assets Gross (Excluding Goodwill)	$16.71B—	——	——
Deferred tax assets	$583M—	$0—	——
Intangible assets — net	$10.06B—	——	——
Other intangible assets—net	$13.89B-4.6%	$14.56B—	——
Other non-current assets	$23.03B-0.4%	$23.11B—	——
Software and Technology Licenses, Net	$23.03B-0.4%	$23.11B—	——
Other Commercial Liabilities	$1.45B-2.7%	$1.49B—	——
Convertible Debt - Current	——	$366M—	——
Accrued Income Taxes, Current	$24M—	——	——
Accrued Liabilities, Current	$1.45B-2.7%	$1.49B—	——
Contingent Consideration Liability (Non-Current)	$29M—	——	——
Debt Maturity - 2024	——	——	——
Debt Maturity - 2027	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$195M—	——	——
Total Carrying Value of Debt	$12.76B—	——	——
Common Stock Shares Outstanding	——	——	——
Convertible Preferred Stock Authorized Shares	5B—	——	——
Convertible Preferred Stock Issued Shares	0—	——	——
Convertible Preferred Stock Outstanding Shares	0—	——	——
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	——	——
Number of Exercisable Options	——	——	——
Number of Vested and Expected to Vest Options	——	——	——
Preferred Stock Par Value Per Share	$0.00—	——	——
Share-Based Payment Award Options Outstanding - Number	6.8M—	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——
Temporary Equity Attributable to Parent	——	$366M—	——
Weighted Average Exercise Price of Outstanding Options	$29.00—	——	——
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——
Other taxes payable	$87M—	——	——
Customer rebates and distributor chargebacks	$406M—	——	——
Allowance for doubtful accounts	$152M—	——	——
Business Combination, Contingent Consideration, Liability	$29M—	——	——
Short-term debt and current portion of long-term debt	$77M-1.3%	$78M—	——
Long-term debt, gross	$12.76B—	——	——
Deferred tax asset, tax receivable agreement	——	——	——
Notional amount, annual incremental decrease	$500M0.0%	$500M—	——
Cost not yet recognized	——	——	——
Estimated excess of current replacement cost over LIFO cost of inventories	$359M—	——	——
Thereafter	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$2.82B—	——	——
2028	——	——	——
2030	——	——	——
Remainder of 2026	——	——	——
2027	——	——	——
2029	——	——	——
Gross Carrying Amount	$12.88B—	——	——
Indefinite- lived intangible impairment	$16.71B—	——	——
Limited Partners Capital Account	——	$16.15B—	——
2028	——	——	——
2029	——	——	——
2030	——	——	——
2027	——	——	——
Remainder of 2026	——	——	——
Noncontrolling interests in subsidiaries	$8.55B—	——	——
Long-Lived Assets	$5.21B—	——	——
Number of classes	3—	——	——
Number of third-party suppliers	——	——	——
Other accrued liabilities	$402M—	——	——
Partners Capital	$16.87B+4.4%	$16.16B-3.5%	$16.74B+0.7%
Preferred Stock, Par or Stated Value Per Share	$0—	——	——
Preferred Stock, Shares Authorized	$5B—	——	——
Preferred Stock, Shares Issued	$0—	——	——
Preferred Stock, Shares Outstanding	$0—	——	——
Recorded Unconditional Purchase Obligation	——	——	——
2024	——	——	——
2025	——	——	——
2026	——	——	——
Recorded Unconditional Purchase Obligation, Due in Remainder of Fiscal Year	——	——	——
2023	——	——	——
Thereafter	——	——	——
Sale of stock, price per share (in dollars per share)	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$6.77M—	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$29—	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——
Expected to vest (in dollars per share)	——	——	——
Exercisable (in dollars per share)	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price	$11.97—	——	——
Tax receivable agreement liability	$3.54B—	$0—	——
Tax receivable agreement liability, current	——	——	——
Tax receivable agreement liability	$3.54B—	——	——
Remainder of Fiscal Year 2024	——	——	——
Remainder of Fiscal Year 2025	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——
Unrecorded Unconditional Purchase Obligation - Due Year Two	——	——	——
Unrecorded Unconditional Purchase Obligation - Due Year Three	——	——	——
Unrecorded Unconditional Purchase Obligation - Due Year Four	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Medline, Inc. .

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Medline, Inc. 's total assets?: Medline, Inc. (MDLN) holds $39.0B in total assets.
How much debt does Medline, Inc. have?: Medline, Inc. carries $12.6B in total debt against $11.3B of shareholders' equity, a debt-to-equity ratio of 1.11.
How much cash does Medline, Inc. have?: Medline, Inc. holds $2.2B in cash and equivalents.
Can Medline, Inc. cover its short-term obligations?: Its current ratio is 4.41 — current assets exceed current liabilities.
Where does Medline, Inc. 's balance sheet data come from?: Every line is extracted from Medline, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.